Generic Name and Formulations:
Cromolyn sodium 100mg/5mL; oral concentrate; preservative-free.
Indications for GASTROCROM:
Mix contents of amp in water and drink. ≥13yrs: 200mg 4 times daily, at regular intervals, ½ hour before meals and at bedtime; may increase if insufficient response within 2–3 weeks. Max 40mg/kg per day; maintain at lowest effective dose.
Mix contents of amp in water and drink. <2yrs: usually not recommended; see literature. 2–12yrs: 100mg 4 times daily, at regular intervals, ½ hour before meals and at bedtime; may increase if insufficient response within 2–3 weeks. Max 40mg/kg per day; maintain at lowest effective dose.
Renal or hepatic dysfunction, reduce dose. Pregnancy (Cat.B). Nursing mothers.
Mast cell stabilizer.
Headache, GI upset, pruritus, myalgia, rash, irritability, malaise.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC